newsfilter
← Latest News
PR Newswire·

Alzamend Neuro Announces Completion of Clinical Portion of Phase II Clinical Trial of AL001 "Lithium in Brain" Study Conducted at Massachusetts General Hospital

Alzamend Neuro, Inc. (Nasdaq: ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment...